Compare · AVTR vs BIO
AVTR vs BIO
Side-by-side comparison of Avantor Inc. (AVTR) and Bio-Rad Laboratories Inc. (BIO): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both AVTR and BIO operate in Biotechnology: Laboratory Analytical Instruments (Industrials), so they compete in similar markets.
- BIO is the larger of the two at $10.44B, about 1.1x AVTR ($9.75B).
- AVTR has been more active in the news (3 items in the past 4 weeks vs 2 for BIO).
- AVTR has more recent analyst coverage (25 ratings vs 12 for BIO).
- Company
- Avantor Inc.
- Bio-Rad Laboratories Inc.
- Price
- $14.41+1.02%
- $390.39+2.45%
- Market cap
- $9.75B
- $10.44B
- 1M return
- -
- +23.48%
- 1Y return
- -
- +31.87%
- Industry
- Biotechnology: Laboratory Analytical Instruments
- Biotechnology: Laboratory Analytical Instruments
- Exchange
- NYSE
- NYSE
- IPO
- 2019
- 1980
- News (4w)
- 3
- 2
- Recent ratings
- 25
- 12
Avantor Inc.
Avantor, Inc. provides products and services to customers in biopharma, healthcare, education and government, advanced technologies, and applied materials industries in the Americas, Europe, Asia, the Middle East, and Africa. The company offers materials and consumables, such as purity chemicals and reagents, lab products and supplies, formulated silicone materials, customized excipients, customized single-use assemblies, process chromatography resins and columns, analytical sample prep kits, education and microbiology products, and clinical trial kits. It also provides equipment and instrumentation products, including filtration systems, virus inactivation systems, incubators, analytical instruments, evaporators, ultra-low-temperature freezers, biological safety cabinets, and critical environment supplies. In addition, the company offers services and specialty procurements comprising onsite lab and production, clinical, equipment, procurement and sourcing, and biopharmaceutical material scale-up and development services. Avantor, Inc. was founded in 1904 and is headquartered in Radnor, Pennsylvania.
Bio-Rad Laboratories Inc.
Bio-Rad Laboratories, Inc. develops, manufactures, and markets life science research and clinical diagnostic products in the United States, Europe, Asia, Canada, and Latin America. The company offers products and systems to separate complex chemical and biological materials, as well as to identify, analyze, and purify components. It operates in two segments, Life Science and Clinical Diagnostics. The Life Science segment develops, manufactures, and markets a range of reagents, apparatus, and laboratory instruments that are used in research techniques, biopharmaceutical production processes, and food testing regimes. It focuses on selected segments of the life sciences market in proteomics, genomics, biopharmaceutical production, cell biology, and food safety. This segment serves universities and medical schools, industrial research organizations, government agencies, pharmaceutical manufacturers, biotechnology researchers, food producers, and food testing laboratories. The Clinical Diagnostics segment designs, manufactures, sells, and supports test systems, informatics systems, test kits, and specialized quality controls for clinical laboratories in the diagnostics market. This segment offers reagents, instruments, and software, which address specific niches within the in vitro diagnostics test market. It sells its products to reference laboratories, hospital laboratories, state newborn screening facilities, physicians' office laboratories, transfusion laboratories, and insurance and forensic testing laboratories. The company offers its products through its direct sales force, as well as through distributors, agents, brokers, and resellers. Bio-Rad Laboratories, Inc. was founded in 1952 and is headquartered in Hercules, California.
Latest AVTR
- President and CEO Ligner Emmanuel covered exercise/tax liability with 29,803 shares, decreasing direct ownership by 4% to 737,334 units (SEC Form 4) to satisfy withholding obligation
- EVP, Chief HR Officer Hankamer Brittany covered exercise/tax liability with 181 shares, decreasing direct ownership by 0.07% to 248,864 units (SEC Form 4) (withholding tax)
- SVP & Chief Accounting Officer Eck Steven W covered exercise/tax liability with 1,385 shares, decreasing direct ownership by 1% to 129,593 units (SEC Form 4) to satisfy withholding tax
- Avantor upgraded by Jefferies with a new price target
- SEC Form 10-Q filed by Avantor Inc.
- Avantor Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- Avantor® Reports Second Quarter 2026 Results
- EVP, Chief Legal & Compliance Sokenu Claudius covered exercise/tax liability with 1,201 shares, decreasing direct ownership by 0.48% to 251,228 units (SEC Form 4) to cover withholding tax
- Avantor Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation, Financial Statements and Exhibits
- Avantor's® NuSil® Brand Expands Partnership with the Population Council to Develop Long-Acting HIV Prevention Product
Latest BIO
- IMDX Reports Second Quarter 2026 Results and Timely Progress on FDA Review of GraftAssureDx
- Bio-Rad Reports Second-Quarter 2026 Financial Results
- Bio-Rad to Report Second-Quarter 2026 Financial Results on Tuesday, August 4, 2026
- RBC Capital Mkts resumed coverage on Bio-Rad Labs with a new price target
- Bio-Rad to Participate in Upcoming Investor Conferences
- Bio-Rad Reports First-Quarter 2026 Financial Results
- Bio-Rad to Report First-Quarter 2026 Financial Results on Thursday, April 30, 2026
- Bio-Rad Labs downgraded by Citigroup with a new price target
- Bio-Rad Reports Fourth-Quarter and Full-Year 2025 Financial Results
- Bio-Rad to Report Fourth Quarter and Full Year 2025 Financial Results on Thursday, February 12, 2026